Eczema Research Study
Researchers at Stanford University are partnering with AbbVie to conduct a study to evaluate the efficacy of an investigational drug in adults ages 18-63 who have atopic dermatitis (eczema) and have had an inadequate response to eczema medication after at least 6 months of current use.
Fast Facts
Have Had Eczema for At Least 3 Years
Taking Eczema Medication for At Least 6 Months Without Success
Compensation Provided
Conducted in Redwood City, CA
Study Background
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of a Treatment for the Management of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Previous Therapy (SWITCH-UP).
Many people with atopic dermatitis (eczema) are not able to meet their treatment targets, even with consistent use of a systemic therapy such as eczema medication. In this research study, we want to examine an investigational drug to assess its safety and effectiveness as compared to other medications.
If you have had atopic dermatitis for at least 3 years, and have been treating it with eczema medication for at least 6 months without relief, you could be a good fit for this research study. Help us advance research to improve treatment options for eczema!
Study Background
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of a Treatment for the Management of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Previous Therapy (SWITCH-UP).
Many people with atopic dermatitis (eczema) are not able to meet their treatment targets, even with consistent use of a systemic therapy such as eczema medication. In this research study, we want to examine an investigational drug to assess its safety and effectiveness as compared to other medications.
If you have had atopic dermatitis for at least 3 years, and have been treating it with eczema medication for at least 6 months without relief, you could be a good fit for this research study. Help us advance research to improve treatment options for eczema!
Additional Information
The goal of this study is to assess the safety and efficacy of a treatment option for adults with atopic dermatitis who have had an inadequate response to previous therapy.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- 18-63 years old
- Have had atopic dermatitis (eczema) for at least 3 years
- Have been taking eczema medication for at least 6 months with no success
Exclusion Criteria:
- No recent (within past 6 months) cerebrovascular accident, heart attack, coronary stenting
- Not currently pregnant, breastfeeding, or planning to become pregnant
- No history of GI perforation (other than due to appendicitis or mechanical injury) or diverticulitis
- No history of significant drug or alcohol abuse within the last 6 months
- No history of an organ transplant which requires continued immunosuppression
- Have not taken any oral JAK inhibitors
If you meet eligibility criteria and are enrolled at the Baseline/Day 1 visit, you will be randomly assigned (like flipping a coin) to receive either one of the study treatments. You will have a 50% chance of receiving either study drug.
This study is comprised of a 35-day Screening Period, followed by an 8-week study treatment period (Period 1), and a 24-week extension study treatment period (Period 2) for all participants that finish Period 1. After the last dose of study drug, there is a 30-day follow-up visit.
Screening visit procedures include:
- informed consent
- reviews of eligibility criteria; medical and surgical history; atopic dermatitis disease activity and history; alcohol, nicotine, and drug history; prior and concomitant medication; and pregnancy avoidance recommendations (for people of childbearing potential)
- adverse event assessment
- TB risk assessment questionnaire and testing
- electronic questionnaires
- vital signs, physical exam, blood and urine tests
- electrocardiogram (ECG)
As a participant, you will be paid $95.00 for each completed study visit, for a total of $855.00 if all visits are completed. You will also be reimbursed for travel expenses that you incur for each completed study visit.
There is no cost for you to participate in our research study.
